article thumbnail

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263
article thumbnail

mRNA Drugs: Pros, Cons, and Prospects

Pharma Mirror

The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021. The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Absci and M2GEN partner to expedite cancer drug development

Pharmaceutical Technology

Under the collaboration, Absci’s generative AI drug creation platform will use M2GEN’s ORIEN AVATAR (AVATAR), a clinical and molecular data set, to speed up the creation of therapies for a range of malignancies and patient profiles.

article thumbnail

Zydus gets FDA approval for antibiotic drug azithromycin

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted final approval to India-based Zydus Lifesciences ‘ 500mg azithromycin tablets for the treatment of bacterial infections. Zydus will manufacture the drug at its formulation facility in Moraiya, Ahmedabad, in the Indian state of Gujarat.

article thumbnail

Drug made from pig intestine helps escape the “trap” of clot-causing immune response

Scienmag

When the body attempts to fight off an infection, immune cells called neutrophils may shoot out spider web-like networks of toxic proteins to help contain the invaders.

article thumbnail

$81 million raised to advance generative AI for drug discovery

Drug Discovery World

Evozyne has closed an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. “In In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability.

Drugs 52
article thumbnail

EC grants approval for Sanofi-GSK’s Covid-19 booster

Pharmaceutical Technology

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.